1. Home
  2. STEX vs GLSI Comparison

STEX vs GLSI Comparison

Compare STEX & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

STEX

Streamex Corp.

N/A

Current Price

$3.46

Market Cap

127.3M

Sector

N/A

ML Signal

N/A

Logo Greenwich LifeSciences Inc.

GLSI

Greenwich LifeSciences Inc.

HOLD

Current Price

$23.60

Market Cap

123.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
STEX
GLSI
Founded
2009
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
127.3M
123.9M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
STEX
GLSI
Price
$3.46
$23.60
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
1
Target Price
$12.00
$50.00
AVG Volume (30 Days)
713.5K
771.4K
Earning Date
02-17-2026
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$13,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.40
$7.78
52 Week High
$14.11
$32.91

Technical Indicators

Market Signals
Indicator
STEX
GLSI
Relative Strength Index (RSI) N/A 59.08
Support Level N/A $20.00
Resistance Level N/A $32.91
Average True Range (ATR) 0.00 4.06
MACD 0.00 -0.50
Stochastic Oscillator 0.00 44.26

Price Performance

Historical Comparison
STEX
GLSI

About STEX Streamex Corp.

Streamex Corp is a vertically integrated technology and infrastructure company. It is focused on the tokenization and digitalization of real-world assets. The group provides institutional-grade solutions that bring traditional commodities and assets on-chain through secure, regulated, and yield-bearing financial instruments. It is committed to delivering transparent, scalable, and compliant digital asset solutions that bridge the gap between traditional finance and blockchain-enabled markets.

About GLSI Greenwich LifeSciences Inc.

Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.

Share on Social Networks: